APOD and myeloid sarcoma: During the last decades, numerous in vitro [51,52,53,54,55] and in vivo [21,56,57,58,59,60] studies in different neuropathologies such as Alzheimer’s disease (AD), Parkinson’s disease (PD), or multiple sclerosis (MS) have postulated that Apo D would be part of the cellular defense machinery against oxidative stress and inflammation, with a clear neuroprotective function [21,61,62,63].